ClinicalTrials.gg
CompletedNCT01978587Updated Mar 18, 2014

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

A Phase 1 interventional study of JTZ-951 in Anemia in Chronic Kidney Disease, sponsored by Akros Pharma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-03-18.

Sponsored by Akros Pharma Inc. (part of Shionogi) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 97 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
586th of 638
6 · median 48
Started
2013
with 37 others
Phase 1
89 of 765
8 open now
Registered
342nd of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 586th largest by enrollment of the 638 interventional ones that give a count, is one of 38 that started in 2013, is one of 89 in phase 1, and was the 342nd registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of hemodialysis on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety of 2 doses of JTZ-951 in subjects with end-stage renal disease (ESRD) receiving hemodialysis

03

Conditions studied

  • Anemia in Chronic Kidney Disease

Keywords

  • End-stage Renal Disease
  • Hemodialysis
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have ESRD and have been receiving maintenance hemodialysis for at least 12 weeks prior to the Screening Visit
  • Body weight (post-dialysis weight) greater than 45.0 kg and a between 20.0 and 40.0 kg/m2 (inclusive) at the Screening Visit

Exclusion criteria

Exclusion Criteria:

  • Acute coronary syndrome (e.g., myocardial infarction) within 1 year prior to admission
  • Uncontrolled hypertension at the Screening Visit or Day -1
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Dose 1 JTZ-951

    Tablets, 1 dose on Day 1 before hemodialysis

    Drug: JTZ-951

  • Experimental
    Dose 2 JTZ-951

    Tablets, 1 dose on Day 8 after hemodialysis

    Drug: JTZ-951

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (maximum concentration) of JTZ-951 when administered before and after hemodialysis

    Time frame: Days 1 to 4 and 8 to 11

  2. tmax (time to reach maximum concentration) of JTZ-951 when administered before and after hemodialysis

    Time frame: Days 1 to 4 and 8 to 11

  3. AUC (area under the concentration-time curve) of JTZ-951 when administered before and after hemodialysis

    Time frame: Days 1 to 4 and 8 to 11

  4. t1/2 (elimination half-life) of JTZ-951 when administered before and after hemodialysis

    Time frame: Days 1 to 4 and 8 to 11

Secondary outcomes

  1. Number of subjects with adverse events

    Time frame: 14 days

  2. Vital signs and ECG (electrocardiogram)

    Time frame: 14 days

07

Study locations

1 site
  • Minneapolis, Minnesota, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Dec 2013 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2013
First posted
Nov 7, 2013
Start
Oct 2013
Primary completionActual
Dec 2013
CompletionActual
Jan 2014
Last update
Mar 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01978587
Lead sponsor
Akros Pharma Inc.
Responsible party
Sponsor
First posted
Nov 7, 2013
Start date
Oct 2013
Primary completion
Dec 2013
Completion
Jan 2014
Last update
Mar 18, 2014

Study contacts

Hideyuki Yamamoto
study chair · Akros Pharma Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enarodustat

Start the discussion